A Phase 3 interventional study of rabeprazole sodium and Placebo in Symptomatic Gastroesophageal Reflux Disease (sGERD), sponsored by Eisai Inc.. Completed at 98 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-02.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 9th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2009, is one of 16 in phase 3, and was the 30th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 17 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 305 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 100 across the 39 interventional studies. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
13 studies in Gastroesophageal Reflux by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 13 finished, 12 (92%) have results posted.
Among the 13 studies in Gastroesophageal Reflux by Eisai Co., Ltd., this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 9 in phase 3, and was the 11th registered.
Eisai Co., Ltd.’s Gastroesophageal Reflux studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 13 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).
KEY INCLUSION CRITERIA:
Male or female, ages 18 through 75 years will be included in the study. Females should be either of nonchildbearing potential or of . Females of childbearing potential must have negative serum and urine pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of starting at Visit 1 and throughout the entire study period and for 1 month after the last dose of study drug. Women using hormonal contraceptives must also be using an additional approved method of contraception starting at Visit 1 and throughout the entire study period and for 1 month after the last dose of study drug. Pregnant or lactating females are excluded. Subjects must have a history of heartburn, identified as their main complaint, for 6 months or longer.Subjects must have documentation of a minimum of 5 moderate to severe heartburn episodes, 3 of which occur during the daytime and 1 of which occurs during the nighttime, during the last 7 days before randomization. Subjects must be able to read, write, and understand the language of the symptom dairy.
KEY EXCLUSION CRITERIA:
Subjects will be excluded from the study if they are found to have erosive esophagitis during esophagogastroduodenoscopy (EGD) at Screening, current or a history of esophageal motility disorders, current or a history of Barrett's esophagus, current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications), current or a history of Zollinger-Ellison syndrome and acid hypersecretory conditions, or current gastric or duodenal ulcer. Subjects will be excluded if they are found to have current or a history of cancer, with the exception of fully excised skin basal cell carcinoma, inflammatory bowel disease, a history of esophageal, gastric and duodenal surgery, except simple closure of a perforated ulcer. Subjects will be excluded who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral (>=20 mg/day prednisone or equivalent), or aspirin (>325 mg/day). Female subjects will be excluded who are pregnant, lactating, or have a positive B-human gonadotropin test at Screening/Baseline. Subjects will be excluded who are known to be (HIV) positive, have participated in another drug study within 30 days prior to screening or are expected to receive an investigational drug during this trial. Subjects who are unwilling to provide will be excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rabeprazole sodium
Drug: Placebo
One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
Also known as: rabeprazole sodium extended release
One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4
Participants completed a daily symptom diary. A heartburn-free day was defined as participant report of 'No Heartburn' from nighttime and daytime of the diary for the same day.
Time frame: Week 4
Change From Baseline in Average Daily Severity Score of Gastroesophageal Reflux Disease (GERD)-Related Symptoms at Week 4
Participants collected GERD-associated symptoms of daytime heartburn, nighttime heartburn and regurgitation in daily symptom diary. Daytime episodes were defined as those that occurred after arising in the morning until retiring in the evening, and nighttime episodes were defined as those that occurred during the night while sleeping or trying to sleep. The severity score was calculated was based on a 5-point Likert scale ranging from 0 (no symptom) to 4 (very severe symptom); higher scores indicated greater disease activity.
Time frame: Baseline and Week 4
Percentage of Participants With Complete Heartburn Relief
Participants completed a daily symptom diary.
Time frame: Week 2 and Week 4
Time to Achieve First 24-Hour Period Without Heartburn
Participants completed a daily symptom diary.
Time frame: Baseline to Week 4
| Milestone | Placebo | RAB ER 50mg |
|---|---|---|
| Started | 147 | 153 |
| Completed | 132 | 137 |
| Not completed | 15 | 16 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lack of efficacy | 4 | 1 |
| Withdrew: Withdrawal of consent | 1 | 4 |
| Withdrew: Other | 2 | 2 |
Participants collected GERD-associated symptoms of daytime heartburn, nighttime heartburn and regurgitation in daily symptom diary. Daytime episodes were defined as those that occurred after arising in the morning until retiring in the evening, and nighttime episodes were defined as those that occurred during the night while sleeping or trying to sleep. The severity score was calculated was based on a 5-point Likert scale ranging from 0 (no symptom) to 4 (very severe symptom); higher scores indicated greater disease activity.
| Scores on a Scale | Placebo | RAB ER 50mg |
|---|---|---|
| Heartburn (Daytime) | -0.82 ± 0.65 | -1.22 ± 0.79 |
| Heartburn (Nighttime) | -0.74 ± 0.72 | -1.17 ± 0.78 |
| Regurgitation | -0.49 ± 0.62 | -0.74 ± 0.81 |
Participants completed a daily symptom diary. A heartburn-free day was defined as participant report of 'No Heartburn' from nighttime and daytime of the diary for the same day.
| Percentage of Days | Placebo | RAB ER 50mg |
|---|---|---|
| Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4 | 21.23 ± 26.8 | 41.14 ± 34.49 |
Participants completed a daily symptom diary.
| Percentage of Participants | Placebo | RAB ER 50mg |
|---|---|---|
| Week 2 (n=147, 148) | 3.4 | 15 |
| Week 4 (n=147, 148) | 7.5 | 22.2 |
Participants completed a daily symptom diary.
| Days | Placebo | RAB ER 50mg |
|---|---|---|
| Time to Achieve First 24-Hour Period Without Heartburn | 14.4 ± 0.84 | 10.6 ± 0.92 |
Collected over For each participant, from the time participant signed the study consent form until resolution or for up to 30 days after study drug discontinuation, whichever came first.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/147 (0.7%) | 0/147 (0%) |
| RAB ER 50mg | — | 0/152 (0%) | 0/152 (0%) |
| Event | Placebo | RAB ER 50mg |
|---|---|---|
| Cholecystitis, acuteHepatobiliary disorders | 1/147 | 0/152 |
| Age, Continuous(Years) | Placebo | RAB ER 50mg | Total |
|---|---|---|---|
| Mean | 44.4 ± 13.32 | 43.8 ± 12.35 | 44.1 ± 12.82 |
| Sex: Female, Male(Participants) | Placebo | RAB ER 50mg | Total |
|---|---|---|---|
| Female | 103 | 105 | 208 |
| Male | 44 | 48 | 92 |
The record gives a start of Jan 2009, a primary completion of Jul 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 6 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole